Biopharma stalwart Ligand Pharmaceuticals is forking over a handful of in-development treatments and adding a $2.5 million sweetener, hoping new partner Viking Therapeutics can get them through midstage study and generate some value.

…read more

Source: Ligand bets a few pipeline drugs will fare better in the hands of another biotech


0 No comments